Through the introduction of different therapeutic transgenes into MSC, apceth Biopharma creates a highly innovative pipeline, comprising two next generation cell-based gene therapy programs, apceth™-201 and apceth™-301.

apceth Biopharma’s vision is to improve patients’ lives by treating incurable diseases with high unmet medical needs in a safer, less toxic and effective way.